Abstract
Lung cancer is the most common cause of deaths related with cancer worldwide and the disease is often at an advanced stage at diagnosis. According to the recent Tumor Node Metastasis classification scheme the vital factor that effects the prognosis and the survival for lung cancer has been known to be the stage of the disease at the time of diagnosis. Besides the stage, histological type and molecular characterization of the tumor and the patient’s performance status are other important prognostic factors in lung cancer patients. According to the new treatment options developed in line with the developments in the molecular and genetic analysis, treatment options and thus the prognosis of lung cancer is affected. Therefore, the prognosis of lung cancer is evaluated and reported in this part considering all these novel developments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):463–73. https://doi.org/10.1016/j.mcna.2018.12.006.
Bryan S, Masoud H, Weir HK, et al. Cancer in Canada: stage at diagnosis. Health Rep. 2018;29(12):21–5.
Önal Ö, Koçer M, Eroğlu HN, et al (2020) Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turk J Med Sci. https://doi.org/10.3906/sag-1912-205.
Göksel S, Karadoğan D. Prevalence and predictors of symptoms in lung cancer patients staged at diagnosis by 18 FDG PET/CT. Turk Thorac J. 2019;20:Supplement 219. https://doi.org/10.5152/TurkThoracJ.2019.219.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. NCCN Version 6.2020-June 15, 2020.
Huang J, Ostroff J. Overview of approach to lung cancer survivors. Uptodate. May 2020.
Glisson BS, Byers LA, Gay MC. Pathobiology and staging of small cell carcinoma of the lung. Uptodate. June 2020.
Wainer Z, Wright GM, Gough K, et al. Impact of sex on prognostic host factors in surgical patients with lung cancer. ANZ J Surg. 2017;87(12):1015–20. https://doi.org/10.1111/ans.13728.
Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.
Chapman AM, Sun KY, Ruestow P, et al. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122–34. https://doi.org/10.1016/j.lungcan.2016.10.010.
Chansky K, Sculier J-P, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4:792–801.
Sakurai H, Asamura H, Goya T, et al. Survival differences by gender for resected non-small cell lung cancer a retrospective analysis of 12,509 cases in a Japanese lung cancer registry study. J Thorac Oncol. 2010;5:1594–601.
Gester F, Paulus A, Sibille AL, et al. Prognostic factors in non small cell lung cancer. Rev Med Liege. 2016;71(1):34–9.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Small cell lung cancer. NCCN Version 3.2020. 5 Feb 2020.
Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30. https://doi.org/10.1097/JTO.0b013e3181d2dcd9.
Norum J, Nieder C. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open. 2018;3(6):e000406. https://doi.org/10.1136/esmoopen-2018-000406.
Pallis AG, Gridelli C. Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer? Cancer Treat Rev. 2010;36:436–41.
O’Mahony S, Nathan S, Mohajer R, et al. Survival prediction in ambulatory patients with stage III/IV non-small cell lung cancer using the palliative performance scale, ECOG, and lung cancer symptom scale. Am J Hosp Palliat Care. 2016;33(4):374–80. https://doi.org/10.1177/1049909115570707.
Huemer F, Lang D, Westphal T, et al. Baseline absolute lymphocyte count and ECOG performance score are associated with survival in advanced non-small cell lung cancer undergoing PD-1/PD-L1 blockade. J Clin Med. 2019;8(7):1014. https://doi.org/10.3390/jcm8071014.
ECOG. Performance status. Available from: https://ecog-acrin.org/resources/ecog-performance-status.
Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81. https://doi.org/10.1016/j.lungcan.2017.07.024.
Ferrigno D, Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis. 2003;59(3):193–8.
Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4(5):702–9. https://doi.org/10.1200/JCO.1986.4.5.702.
Lipford EH 3rd, Eggleston JC, Lillemoe KD, et al. Prognostic factors in surgically resected limited stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol. 1984;8:357.
Takise A, Kodama T, Shimosato Y, et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer. 1988;61:2083.
Cagini L, Monacelli M, Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol. 2000;74:53.
Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substaging in 244 stage I nonsmall- cell lung cancer patients: clinical implications. J Clin Oncol. 1998;16:2468.
Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011;29:4313.
Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34:1223.
Ruffini E, Asioli S, Filosso PL, et al. Significance of the presence of microscopic vascular invasion after complete resection of stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-size categories: did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol. 2011;6:319.
Naito Y, Goto K, Nagai K, et al. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest. 2010;138:1411.
Noma D, Inamura K, Matsuura Y, et al. Prognostic effect of lymphovascular invasion on TNM staging in stage I non-small-cell lung cancer. Clin Lung Cancer. 2018;19(1):e109–22. https://doi.org/10.1016/j.cllc.2017.06.001.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39.
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34. https://doi.org/10.1200/JCO.2012.44.2806.
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. https://doi.org/10.1016/S1470-2045(11)70393-X.
Yu PP, Vose JM, Hayes DF. Genetic cancer susceptibility testing: increased technology, increased complexity. J Clin Oncol. 2015;33(31):3533–4. https://doi.org/10.1200/JCO.2015.63.3628.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.
Hong L, Negrao MV, Dibaj SS, et al. Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC. J Thorac Oncol. 2020;S1556-0864(20):30373–7. https://doi.org/10.1016/j.jtho.2020.04.026.
Cao C, Manganas C, Ang SC, et al. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interact Cardiovasc Thorac Surg. 2013;16(3):244–9. https://doi.org/10.1093/icvts/ivs472.
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86. https://doi.org/10.1016/S0140-6736(09)60737-6.
van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(6):442–50. https://doi.org/10.1093/jnci/djk093.
Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93(6):1807–12. https://doi.org/10.1016/j.athoracsur.
Bradbury P, Sivajohanathan D, Chan A, et al. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18(3):259–273.e8. https://doi.org/10.1016/j.cllc.2016.07.002.
Westeel V, Quoix E, Puyraveau M, et al. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654–64. https://doi.org/10.1016/j.ejca.2013.04.013.
Curran WJ Jr, Paulus R, Langer CJ, et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 [published correction appears in J Natl Cancer Inst. 104(1):79]. J Natl Cancer Inst 103(19):1452–1460. https://doi.org/10.1093/jnci/djr325.
Sun B, Brooks ED, Komaki RU, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: results of a phase 2 clinical trial. Cancer. 2017;123(16):3031–9. https://doi.org/10.1002/cncr.30693.
Widder J, Postmus D, Ubbels JF, et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e291–7. https://doi.org/10.1016/j.ijrobp.2011.03.052.
Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802–9. https://doi.org/10.1016/S1470-2045(12)70242-5.
Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–82. https://doi.org/10.1016/j.ijrobp.2008.11.042.
Matsuo Y, Shibuya K, Nagata Y, et al. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2012;7(2):453–6. https://doi.org/10.1097/JTO.0b013e31823c5b29.
Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42. https://doi.org/10.1200/JCO.2009.23.2272.
Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28(1):29–34.
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–71. https://doi.org/10.1016/S0140-6736(13)62159-5.
Martins RG, D’Amico TA, Loo BW Jr, et al. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. J Natl Compr Canc Netw. 2012;10(5):599–613. https://doi.org/10.6004/jnccn.2012.0062.
Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e341S–68S. https://doi.org/10.1378/chest.12-2361.
Bakitas MA, El-Jawahri A, Farquhar M, et al. The TEAM approach to improving oncology outcomes by incorporating palliative care in practice. J Oncol Pract. 2017;13(9):557–66. https://doi.org/10.1200/JOP.2017.022939.
Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869–76. https://doi.org/10.1200/JCO.2013.49.6489.
Rodrigues G, Videtic GM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1(2):60–71. https://doi.org/10.1016/j.prro.2011.01.005.
Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–55. https://doi.org/10.1016/j.cllc.2014.04.003.
Tallet AV, Azria D, Barlesi F, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol. 2012;7:77. https://doi.org/10.1186/1748-717X-7-77.
Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44. https://doi.org/10.1016/S1470-2045(09)70263-3.
Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–69. https://doi.org/10.1016/S1470-2045(19)30634-5.
Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267–73. https://doi.org/10.1158/1078-0432.CCR-09-0888.
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. https://doi.org/10.1056/NEJMoa1713137.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. https://doi.org/10.1056/NEJMoa1913662.
Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with Gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–50. https://doi.org/10.1200/JCO.2018.78.7994.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46.
Hong X, Xu Q, Yang Z, et al. The value of prognostic factors in Chinese patients with small cell lung cancer: a retrospective study of 999 patients. Clin Res. 2018;J12(2):433–47. https://doi.org/10.1111/crj.12534.
Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25. https://doi.org/10.1016/S1470-2045(17)30318-2.
Horn L, Mansfield AS, Szczęsna A, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Karadoğan, D., Ünsal, M. (2023). Prognosis and Prognostic Factors of Lung Cancer. In: Cingi, C., Yorgancıoğlu, A., Bayar Muluk, N., Cruz, A.A. (eds) Airway Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-22483-6_75-1
Download citation
DOI: https://doi.org/10.1007/978-3-031-22483-6_75-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-22482-9
Online ISBN: 978-3-031-22483-6
eBook Packages: MedicineReference Module Medicine